PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Operating Margin
- Operating margin · 12 months: Value 26.26%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 26.26% | Operating income / revenue. Period ending 2026-06-30. $290.17M ÷ $1.10B × 100 ≈ 26.26% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 290.17M USD | Operating Income (Loss) |
| Revenue | 1.10B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $290.17M | $1.10B | (m) | (m) | (m) | 26.26% |
| 2026-03-31 | $309.41M | $1.09B | (m) | (m) | (m) | 28.42% |
| 2025-12-31 | $322.35M | $1.10B | (m) | (m) | (m) | 29.21% |
| 2025-09-30 | $331.82M | $1.11B | (m) | (m) | (m) | 29.88% |
| 2025-06-30 | $336.49M | $1.12B | (m) | (m) | (m) | 30.04% |
| 2025-03-31 | $336.77M | $1.14B | (m) | (m) | (m) | 29.60% |
| 2024-12-31 | $330.50M | $1.12B | (m) | (m) | (m) | 29.56% |
| 2024-09-30 | $325.37M | $1.11B | (m) | (m) | (m) | 29.30% |
| 2024-06-30 | $329.28M | $1.11B | (m) | (m) | (m) | 29.58% |
| 2024-03-31 | $342.43M | $1.13B | (m) | (m) | (m) | 30.43% |
| 2023-12-31 | $-20.72M | $1.13B | (m) | (m) | (m) | -1.83% |
| 2023-09-30 | $-20.37M | $1.13B | (m) | (m) | (m) | -1.81% |
| 2023-06-30 | $-24.23M | $1.13B | (m) | (m) | (m) | -2.14% |
| 2023-03-31 | $-22.41M | $1.13B | (m) | (m) | (m) | -1.99% |
| 2022-12-31 | $336.01M | $1.11B | (m) | (m) | (m) | 30.30% |
| 2022-09-30 | $331.42M | $1.11B | (m) | (m) | (m) | 29.92% |
| 2022-06-30 | $325.59M | $1.09B | (m) | (m) | (m) | 29.74% |
| 2022-03-31 | $329.92M | $1.09B | (m) | (m) | (m) | 30.36% |
| 2021-12-31 | $323.43M | $1.06B | (m) | (m) | (m) | 30.58% |
| 2021-09-30 | $314.28M | $1.02B | (m) | (m) | (m) | 30.75% |
| 2021-06-30 | $308.63M | $983.15M | (m) | (m) | (m) | 31.39% |
| 2021-03-31 | $297.40M | $943.37M | (m) | (m) | (m) | 31.53% |
| 2020-12-31 | $300.38M | $956.84M | (m) | (m) | (m) | 31.39% |
| 2020-09-30 | $303.34M | $959.60M | (m) | (m) | (m) | 31.61% |
| 2020-06-30 | $299.79M | $960.25M | (m) | (m) | (m) | 31.22% |
| 2020-03-31 | $291.15M | $963.01M | (m) | (m) | (m) | 30.23% |
| 2019-12-31 | $63.79M | $952.80M | (m) | (m) | (m) | 6.69% |
| 2019-09-30 | $64.93M | $952.66M | (m) | (m) | (m) | 6.82% |
| 2019-06-30 | $66.50M | $953.95M | (m) | (m) | (m) | 6.97% |
| 2019-03-31 | $67.50M | $975.78M | (m) | (m) | (m) | 6.92% |
| 2018-12-31 | $198.25M | $990.72M | (m) | (m) | (m) | 20.01% |
| 2018-09-30 | $204.60M | $1.02B | (m) | (m) | (m) | 20.06% |
| 2018-06-30 | $209.40M | $1.04B | (m) | (m) | (m) | 20.16% |
| 2018-03-31 | $215.87M | $1.04B | (m) | (m) | (m) | 20.73% |
| 2017-12-31 | $291.74M | $1.03B | (m) | (m) | (m) | 28.44% |
| 2017-09-30 | $277.53M | $972.03M | (m) | (m) | (m) | 28.55% |
| 2017-06-30 | $272.43M | $929.06M | (m) | (m) | (m) | 29.32% |
| 2017-03-31 | $205.61M | $882.06M | (m) | (m) | (m) | 23.31% |
| 2016-12-31 | $217.83M | $849.25M | (m) | (m) | (m) | 25.65% |
| 2016-09-30 | $211.18M | $832.68M | (m) | (m) | (m) | 25.36% |
| 2016-06-30 | $210.02M | $823.69M | (m) | (m) | (m) | 25.50% |
| 2016-03-31 | $260.31M | $806.25M | (m) | (m) | (m) | 32.29% |
| 2015-12-31 | $256.29M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $250.64M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $227.26M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $207.56M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $191.27M | $672.13M | (m) | (m) | (m) | 28.46% |
| 2014-09-30 | $174.73M | $619.39M | (m) | (m) | (m) | 28.21% |
| 2014-06-30 | $181.98M | $605.07M | (m) | (m) | (m) | 30.08% |
| 2014-03-31 | $188.62M | $601.88M | (m) | (m) | (m) | 31.34% |
| 2013-12-31 | $193.83M | $612.14M | (m) | (m) | (m) | 31.67% |
| 2013-09-30 | $200.10M | $626.16M | (m) | (m) | (m) | 31.96% |
| 2013-06-30 | $197.49M | $619.57M | (m) | (m) | (m) | 31.88% |
| 2013-03-31 | $191.88M | $623.60M | (m) | (m) | (m) | 30.77% |
| 2012-12-31 | $164.27M | $603.08M | (m) | (m) | (m) | 27.24% |
| 2012-09-30 | $141.18M | $549.10M | (m) | (m) | (m) | 25.71% |
| 2012-06-30 | $119.42M | $492.79M | (m) | (m) | (m) | 24.23% |
| 2012-03-31 | $102.82M | $441.08M | (m) | (m) | (m) | 23.31% |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $76.14M | $336.51M | (m) | (m) | (m) | 22.63% |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $78.33M | $292.60M | (m) | (m) | (m) | 26.77% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |